Bridelia ferruginea inhibits key carbohydrate digesting enzyme and intestinal glucose absorption and modulates glucose metabolism in diabetic rats.
Arch Physiol Biochem
; 129(3): 671-681, 2023 Jun.
Article
in En
| MEDLINE
| ID: mdl-33370536
ABSTRACT
The antidiabetic potentials of the dichloromethene, ethyl acetate, butanol and aqueous fractions of Bridelia ferruginea leaves were investigated using in vitro, ex vivo and in vivo models. In vitro and ex vivo antidiabetic activities revealed the butanol (BFBF) to be the most active of the fractions, and thus selected for in vivo study. Diabetes was induced using the fructose-streptozotocin model. Treatments with BFBF significantly reduced blood glucose level and improved glucose tolerance, serum insulin level and sensitivity as well as suppressed hyperlipidaemia and serum nephropathy markers. Histopathological analysis revealed the ability of BFBF to protect and regenerate pancreatic ß-cells. BFBF significantly elevated glutathione level, catalase and superoxide dismutase activities, while depleting MDA level in serums and kidney of diabetic rats. Phenols, steroids, terpenoids, aliphatic and aromatic compounds were identified in the fractions following GC-MS analysis. Overall, results from this study propose that BFBF possess potent antidiabetic activity.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Diabetes Mellitus, Experimental
/
Glucose
Language:
En
Journal:
Arch Physiol Biochem
Year:
2023
Type:
Article
Affiliation country:
South Africa